Our Priorities & Progress
Our current program focuses on three priority areas of work:
Evidence Identification & Evaluation
Ongoing analysis of the medical literature to surface drugs with the strongest evidence for cancer impact, with continuous reassessment as new data emerge.
Research to Address Evidence Gaps
Active partnerships with research institutions and health systems to deepen evidence for prioritized candidates, including analyses using clinical practice data and clinical studies where gaps remain.
Clinical Awareness & Use Pathways
Development of clinician-facing evidence materials alongside analysis of regulatory and evidentiary pathways that shape how off-patent drugs can be evaluated and used in clinical care, informed by our published, peer-reviewed analysis of nonprofit-led drug repurposing.
Our Pipeline to Date
Our pipeline reflects continuous analysis and evaluation. As drugs become generic and new clinical data emerge, our AI-powered review adds and reassesses candidates over time.
Reboot Rx has analyzed over 500,000 published studies and surfaced over 100 generic drugs with clinical data for potential repurposing in cancer. From these, we selected 26 candidates with the most consistent evidence related to repurposing and prioritized 5 based on the totality of existing evidence, accessibility, low cost, and patient need. Through conversations with clinical experts, three of these (for prostate cancer, colorectal cancer, and bladder cancer) were prioritized based on the body of published literature.
Our first evidence resource for clinicians focuses on the repurposing opportunity in prostate cancer, where 5-alpha reductase inhibitors have been evaluated in patients undergoing active surveillance.
For repurposing candidates with emerging evidence signals, we are collaborating with partners such as the National Cancer Institute, Veterans Health Administration, and leading cancer centers to support further study.
PIPELINE HIGHLIGHT
5-alpha reductase inhibitors (5-ARIs) for patients with prostate cancer on active surveillance
The 5-ARIs are not currently FDA-approved for treatment or management of prostate cancer. However, their association with delaying disease progression in patients with prostate cancer has been reported in published studies.
Reboot Rx has developed an online resource for clinicians that brings together the published studies, safety considerations, mechanism of action, and drug access information in one place.
Clinicians: Review the evidence
Reboot Rx surfaces and organizes evidence. Our evidence resources are for informational purposes only and are not intended to provide medical advice.
Regulatory Policy Insights
We conduct and publish peer-reviewed analyses and policy white papers examining how nonprofit and non-manufacturer organizations can support the evaluation and regulatory approval of new uses for generic drugs. This work analyzes barriers that limit clinical consideration of off-patent treatments and identifies feasible pathways for advancing new uses when evidence is robust.
Across regulatory, legal, and policy analyses, we examine how nonprofit models can help coordinate evidence, regulatory submissions, and health system processes that currently lack a natural institutional owner.
Read our policy insights
Pathways for non-manufacturers to drive generic drug repurposing for cancer in the U.S. (Frontiers in Pharmacology)
Clearing the Path for New Uses for Generic Drugs (Federation of American Scientists)
Nonprofits Are Ready to Repurpose Generic Drugs (Petrie-Flom Center at Harvard Law School)
Future Priorities
With additional investment, Reboot Rx will:
Expand analytical capacity to evaluate broader and more diverse treatment candidates.
Strengthen the evidence base through deeper evaluation and targeted research collaborations with academic institutions and health systems.
Develop structured decision tools to assess guideline readiness and clarify how evidence-based generics could fit into existing clinical care pathways.
Clarify system-level pathways by analyzing regulatory, payer, and health system requirements that shape whether off-patent drugs can be evaluated, approved, and used in routine care.
Working with Reboot Rx
We partner with clinicians, researchers, health system leaders, and philanthropic funders to help move affordable cancer treatments toward clinical use.
We contribute an independent analysis consisting of systematic evidence synthesis and rigorous prioritization to help partners identify promising generics. Our collaborators bring clinical insight and research expertise. Together, we focus on clarifying evidence and navigating the pathways that determine whether promising off-patent drugs can reach patients.
If you're interested in working with us to advance repurposing opportunities, we welcome a conversation.